episode 80: “China Rx: America’s Dependence on China for Medicine” with Rosemary Gibson and Frank Gaffney

“Millions of Americans are taking prescription and over-the-counter drugs made in China and don’t know it and neither do their doctors. These are prescription drugs in the legal supply chain that are distributed to U.S. hospitals, sold in corner drug stores and grocery store pharmacies, and distributed to military hospitals and clinics around the world,” explains Rosemary Gibson.

We cannot make aspirin in the United States. We cannot make penicillin in the United States. Nor can we make generic antibiotics.

China’s aim is to become the pharmacy to the world, and it is on track to achieve it.

Join me as I talk with Rosemary Gibson, author of “China Rx: Exposing the Risks of America’s Dependence on China for Medicine” and Frank Gaffney Vice Chairman of the Committee for the Present Danger: China about the existential risks posed by the United States’ dependence on China for drugs and essential healthcare supplies.

“And I’m sure you may have seen the statement from the Chinese government media actually threatening to withhold drugs and to throw the United States into the ocean of hell of coronavirus. And there were threats before, but this the most brazen.”

“So, here we have a situation where you have a global pandemic and the whole world depends on a single country for those core chemicals to make critical drugs.”

If China shut the door on exports of medicines and their key ingredients and raw materials, U.S. hospitals and military hospitals and clinics would cease to function within months, if not days.
China produces 10% of our generic drugs but more critically, almost 90% of the core chemicals and drug ingredients are controlled by China.

The Global Pandemic is bringing home many unpleasant truths and this is one of the harshest.

Learn more here.

(We had some technical issues with the Zoom app, I occasionally couldn’t hear Rosemary or Frank. But the subject matter is so timely and vital we’re going ahead with publishing our conversation.)